Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease
Yoshimasa Aso, Kanako Kato, Shintaro Sakurai, et al.
International Journal of Clinical Practice (2019) Vol. 73, Iss. 5, pp. e13335-e13335
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 202
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, et al.
Metabolism (2021) Vol. 126, pp. 154925-154925
Open Access | Times Cited: 163
Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna Attia, Samir Softic, Marialena Mouzaki
Clinical and Translational Science (2020) Vol. 14, Iss. 1, pp. 11-19
Open Access | Times Cited: 110
Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
Niki Katsiki, Ele Ferrannini
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 12, pp. 107723-107723
Open Access | Times Cited: 78
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Karolina Drożdż, Katarzyna Nabrdalik, Weronika Hajzler, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 75
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, et al.
Journal of Gastroenterology and Hepatology (2021) Vol. 36, Iss. 10, pp. 2952-2959
Open Access | Times Cited: 71
Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Qiong Wei, Xinyue Xu, Li Guo, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 66
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
Yunpeng Gu, Lei Sun, Wei Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Camilla Anastasio, Isabella Donisi, Vitale Del Vecchio, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 9
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice, Maryam Ghani, Janahan Suthakar, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2706-2721
Open Access | Times Cited: 8
Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease
Hamza El Hadi, Angelo Di Vincenzo, Roberto Vettor, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2215-2215
Open Access | Times Cited: 60
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Laurie L. Baggio, Elodie M. Varin, Jacqueline A. Koehler, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 54
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, et al.
Diabetes/Metabolism Research and Reviews (2020) Vol. 37, Iss. 6
Closed Access | Times Cited: 51
Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 50
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Dongmei Wang, J. Y. Liu, Ling Zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
Zijie Jin, Yan Yuan, Zheng Chen, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 8, pp. 108558-108558
Closed Access | Times Cited: 21
Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids
Zijie Jin, Ruotong Yin, Yan Yuan, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116167-116167
Closed Access | Times Cited: 7
Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function
Zakaria Hamdan, Yusri Abdel-Hafez, Ahmad Enaya, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
Chelsea S. Pan, Takara L. Stanley
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 41
Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
Cheng Han Ng, Snow Yunni Lin, Yip Han Chin, et al.
Endocrine Practice (2021) Vol. 28, Iss. 2, pp. 223-230
Closed Access | Times Cited: 40
GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
Hongle Yan, Chunyi Huang, Xuejun Shen, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 23
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
Manjun Deng, Yonghao Wen, Jingxin Yan, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 5
A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
Jonathan James Hyett Bray, Harri Foster‐Davies, Jeffrey W. Stephens
Diabetes Research and Clinical Practice (2020) Vol. 168, pp. 108368-108368
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top